🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication

RecruitingPhase 4Ages 18 Years - anyAllDow University of Health Sciences
NCT07344506 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study, titled CURE-H. Pylori, is a three-arm, parallel-group, open-label, randomized controlled trial designed to evaluate the effectiveness of Dexlansoprazole, Lansoprazole, and Vonoprazan in combination with Levofloxacin and Amoxicillin for Helicobacter pylori eradication. H. pylori infection is a significant health issue worldwide, with an estimated prevalence of 44% globally and around 60% in Pakistan, leading to gastritis, peptic ulcer disease, and increased risks of gastric cancer and mucosa-associated lymphoid tissue lymphoma. Despite the widespread use of PPI-based triple therapies, treatment efficacy has decreased due to increasing antibiotic resistance, especially to Clarithromycin and Metronidazole. This study aims to assess the eradication rate of H. pylori in patients receiving either Dexlansoprazole 60mg, Lansoprazole 30mg, or Vonoprazan 20mg, each combined with Levofl

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Adult patients of both sexes, presenting to the out-patient departments of the participating healthcare centres, and diagnosed through a UBT to have H.Pylori infection by their physician will be eligible for enrolment in the study, but are currently not receiving any treatment for H.Pylori infection. Exclusion Criteria: 1. Those who will not provide written consent for the study. 2. Patients with severe mental disability, 3. pregnant or lactating women, 4. those who are already on treatment for H.Pylori infection, and 5. those who have received any antibiotic within the last two weeks of enrolling in this study will be excluded. 6. Patients with known previous documented drug allergies for the current regime will be excluded from the trial
💊

What it tests

  • Arm 1: Dexlansoprazole + Levofloxacin-Based Triple Therapy
  • Arm 2: Lansoprazole + Levofloxacin-Based Triple Therapy
  • Arm 3: Vonoprazan + Levofloxacin-Based Triple Therapy
📍

Where

1 site
Sindh Institute of Advanced Endoscopy and Gastroenterology (SIAG), DUHS
Karachi, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy